Advertisement
UK markets open in 7 hours 12 minutes
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • CRUDE OIL

    78.33
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    2,323.60
    -0.60 (-0.03%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • Bitcoin GBP

    49,988.58
    -566.51 (-1.12%)
     
  • CMC Crypto 200

    1,293.90
    -71.22 (-5.22%)
     
  • NASDAQ Composite

    16,332.56
    -16.69 (-0.10%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

BioCryst to Report First Quarter 2024 Financial Results on May 6

BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

ADVERTISEMENT

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com